Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer.
Atezolizumab
Breast cancer
Posterior reversible encephalopathy
Journal
Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
09
2021
revised:
09
03
2022
accepted:
10
03
2022
pubmed:
20
3
2022
medline:
18
5
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
Posterior reversible encephalopathy syndrome (PRES) is a complex neurological disorder with multiple clinical manifestations including headaches, seizures, and altered mental status. It is associated with many conditions including malignancy and medications including chemotherapy and immunotherapy. We report the case of a 56-year old female with a history of advanced triple negative breast cancer treated with atezolizumab (a PD-L1 inhibitor), paclitaxel and ipatasertib (investigational AKT inhibitor), who developed hypertension, confusion, and imaging findings consistent with PRES.
Identifiants
pubmed: 35305364
pii: S2468-2942(22)00039-9
doi: 10.1016/j.ctarc.2022.100548
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
atezolizumab
52CMI0WC3Y
Paclitaxel
P88XT4IS4D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100548Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.